Navigation Links
Dendreon Reports First Quarter 2011 Financial Results
Date:5/2/2011

target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. DENDREON CORPORATIONCONSOLI
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2
... China , May 18 /PRNewswire-Asia/ -- Ningbo ... was officially put into operation, successfully being used in ... steel slag as an absorbent,instead of lime or other ... of lime agents, the replacement reduces SO2 emissions by,more ...
... CLEVELAND, Ohio , May 18, 2010 Simbionix USA Corporation,the ... and the healthcare industry, is proud to,report that their ANGIO Mentor virtual ... Societies in April 2010 for,the training and certification of vascular ... , , ...
... ... with ultra-fine finishing capabilities , ... (PRWEB) -- The increased miniaturization of medical devices such as surgical instruments ... the integral items that have helped to facilitate the use of miniaturized medical devices ...
Cached Biology Technology:TAIJI Announces Official Operation of Its Sintering FGD Project for Tangshan 2Simbionix ANGIO Mentor Plays Important Role in Physician Training and Certification 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 3
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... shows that prenatal health care professionals are concerned about ... providing effective counseling. Rates of excessive weight gain ... adverse health outcomes for mothers and children, have increased ... care providers agree that weight gain is an important ...
... Palo Alto, CATo engineer better, more productive crops ... look at how the sensor-laden membranes surrounding cells ... interact with the environment and neighboring cells to ... about how proteins interact with these protective structures. ...
... to three-dimensional puzzles, Rubik,s Cube pales in comparison with ... Gordon and collaborators Chuck DeMets of the University of ... in Pasadena, Calif., have just put the finishing touches ... of the relative movements of the interlocking tectonic plates ...
Cached Biology News:Prenatal health-care providers inconsistent in weight-gain counseling 2Cracking the plant-cell membrane code 2Tectonics: Precision is hallmark of 20-year study 2Tectonics: Precision is hallmark of 20-year study 3
... tube luminometer provides the sensitivity and versatility ... Advanced digital photon counting with selected photomultipliers ... spectral demands. Equipped with up to 2 ... for reporter gene assays as well as ...
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Cell Culture Flask, nontreated polystyrene...
Biology Products: